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and net monetary benefit calculations. Sensitive variables include abiraterone
costs and neutropenia costs of mitozantrone. Even assuming most patients are
severely ill to match sites with sicker populations, the relative cost-effectiveness
does not change; abiraterone favored and cabazitaxel always above tolerable
thresholds. CONCLUSIONS: Abiraterone is the most cost effective given WTP of
$100,000. Despite slightly higher survival with cabazitaxel, it is never cost-effective
with high drug andneutropenia costs. Even for care siteswith relatively ill patients,
abiraterone remains cost-effective.
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OBJECTIVES: Cancer is a risk factor to develop deep vein thrombosis (DVT), pulmo-
nary embolism (PE) or relapse of these conditions. Alternatives to oral anticoagu-
lants need to be evaluated. The objective of this study was to perform an economic
evaluation of anticoagulant therapies in adult patients with cancer (solid tumors),
from the Social SecurityMexican Institute (IMSS) perspective.METHODS:One-year
medical direct costs (2011 US$) and health consequences were estimated by a
Markov model (one-week cycles). Effectiveness measures were reduction in cases
of DVT and PE (per 1000 patients). A meta-analysis was performed to estimate
transition probabilities. Alternatives considered in the assessment were: warfarin
(5mg/day); dalteparin (not listed in Mexican formulary, 5000 IU/day); enoxaparin
(40 mg/day); nadroparin (5700 IU/day); unfractionated heparin (UFH) plus warfarin
(10000 IU/day5 mg/day) and no prophylaxis. Resource use and costs were ob-
tained through IMSS databases (dalteparin acquisition cost was provided by man-
ufacturer). Univariate sensitivity analysis was performed. Acceptability curves
were constructed. RESULTS: Estimated cases of DVT avoidedwere: warfarin 276 (CI
95% 271–281); dalteparin 47 (46–48); enoxaparin 107 (105–109); nadroparin 97 (95–
99); UFH 127 (124–130) and no prophylaxis 317 (310–323). Regarding PE prevention,
outcomes were: warfarin 116 (114–118); dalteparin 16 (16–16); enoxaparin 23 (23–
23); nadroparin 15 (15–15); UFH 26 (25–27) andno prophylaxis 61 (60– 62). Per patient
annual costs were: warfarin $1908.32 ($1851.38-$1918.42); dalteparin $2298.82
($2268.41-$2329.22); enoxaparin $3713.36 ($3634.27-$3792.46); nadroparin $2,648.14
($2603.54-$2692.76); UFH $1884.90 ($1851.38-$1918.42) and no prophylaxis $2667.81
($2619.18-$2716.42). For both DVT and PE, ICER=s of dalteparin, enoxaparin and
nadroparin were $1.72, $3.93; $10.70, $19.44, $4.15 and $7.35, respectively. In pre-
vention of bothDVTand PE, dalteparin ismore effective and less costly than enoxa-
parin, nadroparin and no prophylaxis. CONCLUSIONS: Dalteparin is a potential
cost-effective antithrombotic therapy in adult patients with cancer in Mexico.
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OBJECTIVES: To evaluate the cost-effectiveness of Everolimus as second-line of
treatment compared with sorafenib in adult patients with metastatic renal cell
carcinoma, from the perspective of the Mexican Public Health Institution.
METHODS:We compare the results obtained in treating renal cancer patients with
either sorafenib or everolimus, previously treated with sunitinib in Mexico. We
developed amarkovmodel in a two-year period among three possible health states
(stable, progression and death). Overall survival and progression-free survivalwere
used as effectivenessmeasures and the sources of this informationwere published
articles. We considered the costs of drugs, best-supportive care and follow-up
(stable disease and progression); drug costs of everolimus and sorafenib only apply
to stable patients. The costs of medical resources correspond to the costs of med-
ical care in tertiary care systems. All costs were calculated in 2010 Mexican pesos.
An incremental analysis of cost and results in health was realized, to compare
everolimus and sorafenib. A sensitivity analysis was also accomplished (determin-
istic and probabilistic). The discount rate applied to costs and effectivenesswas 5%.
RESULTS: Patients with everolimus obtained more overall survival (14.37 vs. 7.73
months) and progression-free survival (4.83 vs. 3.88 months) than those that used
sorafenib. Everolimus resulted as the alternative with less average total cost than
sorafenib: $391,765.00 and $454,802.00 respectively. Everolimus is a dominant op-
tion compared with sorafenib. Sensitivity analysis showed robustness in the
results. CONCLUSIONS: Everolimus is the cheapest treatment option and saving of
resources, which significantly increases the survival of patients and provides lon-
ger progression-free and more overall survival versus sorafenib.
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OBJECTIVES:To evaluatewhether the use of bevacizumab in first line treatment for
patients with advanced ovarian cancer represents a cost-effective strategy for
health institutions in Mexico. METHODS: Ovarian Cancer is the sixth most com-
mon cancer and second gynecologic malignancy worldwide, with approximately
190,000 new cases per year. Ovarian cancer is considered highly lethal for their
growth characteristics, low symptoms and recurrence. A complete economic eval-
uation of cost-effectiveness was performed in womenwith ovarian cancer stage III
and IV, classified as high risk, taking carboplatin  paclitaxel (CP) and bevaci-
zumab carboplatinpaclitaxel (BCP) as comparators. The 1st cycle, carboplatin
paclitaxel are administered alone; from 2nd to 6th is added bevacizumab
(7.5 mg/kg). From cycle 7, all patients with no evidence of disease progression
received maintenance bevacizumab as monotherapy, giving a maximum of 18
cycles. The progression was emulated with aMarkovmodel considering the stages
of: progression free survival, progression and death in a 11.5 year time horizon.
Costs are expressed in US dollars. RESULTS: BCP gained more months with pro-
gression free survival compared with CP (16.77 vs. 14.40). BCP obtained 40.89
months of overall survival versus 31.17 with CP, generating a 36% increase in over-
all life expectancy. The Incremental Cost Effectiveness Ratio (ICER) for BCP is
$25,544 per year of additional life year gained with respect the use of CP. According
to the International Monetary Fund, the Gross Domestic Product (GDP) for Mexico
in 2011 was $9471. For a threshold of 3 times this value (3 GDP per capita: $28,413),
the use of BCP in advanced ovarian cancer would be cost-effective. CONCLUSIONS:
BCP is an alternative that substantially increases the patient overall survival ex-
pectancy. It also lies within the international cost-effectiveness threshold.
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OBJECTIVES:Assesswhether the use of Erlotinib as 1st line treatment inmetastatic
or advanced Non Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth
Factor Receptor (EGFR) mutation positive, is a dominant alternative from the per-
spective of public health system in Mexico. METHODS: It was developed a cost-
utility analysis using a Markov model with monthly cycles stages: response to
treatment, stable disease, disease progression and death in a time horizon of 5
years. The costing method is the direct medical costs and the main outcome mea-
sures were QALY’s and total cost of treatment per patient. The drugs compared in
the study were Erlotinib, Gefitinib and chemotherapy with Gemcitabine plus Car-
boplatin. Costs are expressed in US dollars. RESULTS: Erlotinib was the alternative
that provided a greater number of QALY’s (1.49) compared with Gefitinib (1.32) and
chemotherapy with Carboplatin (1.07). Furthermore, treatment with Erlotinib was
the least expensive with a cost per patient of $51,249 on a horizon of 5 years while
the cost of Gefitinib was $ 53,817 per patient and the QT with Gemcitabine 
Carboplatin $53,258 per patient. This implies that the dominant treatment for
these patients (NSCLC and positive EGFR mutation) is Erlotinib with a cost-effec-
tiveness average of $34,456. The dominance results of treatment with Erlotinib
were consistent with sensitivity analysis, which provides robustness to the results.
CONCLUSIONS: Considering the average annual costs, Erlotinib represents savings
for the health sector from $402 (versus Gemcitabine  Carboplatin) to $514 (vs
Gefitinib) for each patient according to its comparator in 1 year. Therefore, under
the context of public health system inMexico, treatment with Erlotinib was shown
to be a cost-effective treatment and dominant over other treatment alternatives
considered in this study for patients with NSCLC and EGFR mutation.
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OBJECTIVES: The aim of this study is to assess efficiency of adding rituximab to
fludarabine and cyclophosphamide (R-FC versus FC) for the treatment of previ-
ously untreated chronic lymphocytic leukemia in Ukraine. METHODS: A cost-ef-
fectiveness analysis was performed from a health care perspective over a 20 year
horizon with 3% discounting rate. Markov model in Excel program (2007) with
cohort simulation was applied. Three-state model (no disease progress, relapse,
and death) was run using one month cycle time. The outcome data were retrieved
from a randomized controlled trial publication. One-way sensitivity analysis was
performed to assess robustness of the results. RESULTS: The incremental life ex-
pectancy increase was 3.27 months on R-FC in comparison to FC scheme. The
expected costs associated with FC scheme are equal to $28,105 and with FC-R
scheme to $41,850. R-FC was associated with incremental 1.3 quality-adjusted life-
years (QALYs) compared to FC and resulted in an incremental cost-effectiveness
ratio of $10,588 per QALY from health care perspective. Results were themost sensi-
tive tounitdrugcost for rituximab (costsdeviation$1.77-3.88permg).CONCLUSIONS:
The World Health Organization recommends to consider drugs cost-effective if their
incremental cost per QALY is less than 3 gross domestic product per capita in the
country ($6,700/per capita inUkraine). Under these recommendations, R-FC scheme is
seen as cost-effective in Ukrainian health-care setting.
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OBJECTIVES: The objective of this researchwas to determine the incremental cost-
effectiveness, from a US societal perspective, of adding temozolomide to the pre-
vious standard of care (radiotherapy only) for the adjuvant treatment of newly
diagnosed glioblastoma. METHODS: A Markov model with a one-month cycle
length and five-year time horizon was constructed in Microsoft Excel. All model
parameters were obtained from relevant peer-reviewed literature based on sys-
tematic review. Transition probabilities were calculated using survival data from
randomized controlled trials comparing temozolomide plus radiotherapy versus
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